Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197506 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
A Phase 2 study of Glioblastoma and Gliosarcoma, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 3
- Study locations
NCT03197506 is a Phase 2 study of Glioblastoma and Gliosarcoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 52 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (52% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03197506, a Phase 2 study of Glioblastoma and Gliosarcoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies the side effects and how well pembrolizumab works in combination with standard therapy in treating patients with glioblastoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in the chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving pembrolizumab and standard therapy comprising of temozolomide and radiation therapy may kill tumor cells.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- RADIATION External Beam Radiation Therapy
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
- DRUG Temozolomide
Study Locations (3)
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2028-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03197506
The ClinicalTrials.gov registry entry for NCT03197506 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (52% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03197506 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03197506 about?
NCT03197506 is a clinical study titled "Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma". This phase II trial studies the side effects and how well pembrolizumab works in combination with standard therapy in treating patients with glioblastoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ...
What is the current status of trial NCT03197506?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2018-01-15. Estimated completion is 2028-06-06.
What conditions does trial NCT03197506 study?
This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma.
What interventions are being tested in trial NCT03197506?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), External Beam Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT03197506?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03197506 being conducted?
This trial has 3 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.